These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 32771343

  • 1. Successful Drug Rechallenge Following Severe Acute Alectinib-induced Interstitial Lung Disease in a Patient With Advanced ALK-rearranged Lung Adenocarcinoma.
    Gadotti LL, Nogueira Amorim Canedo FS, Ribeiro MFSA, Sacardo KP, Saddi R, Machado Alessi JV, de Abreu Testagrossa L, Katz A.
    Clin Lung Cancer; 2021 May; 22(3):e481-e486. PubMed ID: 32771343
    [No Abstract] [Full Text] [Related]

  • 2. Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease.
    Huang JR, Chou CW, Chao HS.
    J Oncol Pharm Pract; 2021 Jul; 27(5):1311-1314. PubMed ID: 33054691
    [Abstract] [Full Text] [Related]

  • 3. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib.
    Kaira K, Naruse I, Shimizu K, Asao T.
    J Cancer Res Ther; 2020 Jul; 16(4):919-921. PubMed ID: 32930141
    [Abstract] [Full Text] [Related]

  • 4. Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib.
    Zhang Y, Qin Y, Xu H, Yao Q, Gao Y, Feng Y, Ren J.
    Pathol Oncol Res; 2021 Jul; 27():637745. PubMed ID: 34257603
    [Abstract] [Full Text] [Related]

  • 5. Interstitial lung disease induced by alectinib (CH5424802/RO5424802).
    Ikeda S, Yoshioka H, Arita M, Sakai T, Sone N, Nishiyama A, Niwa T, Hotta M, Tanaka T, Ishida T.
    Jpn J Clin Oncol; 2015 Feb; 45(2):221-4. PubMed ID: 25398579
    [Abstract] [Full Text] [Related]

  • 6. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
    Yamamoto Y, Okamoto I, Otsubo K, Iwama E, Hamada N, Harada T, Takayama K, Nakanishi Y.
    Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
    [Abstract] [Full Text] [Related]

  • 7. Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung.
    Balzer BWR, Loo C, Wegner EA, Nath CE, Lee S, Smith C, Lewis CR, Trahair TN, Anazodo AC.
    Pediatr Hematol Oncol; 2018 Oct; 35(7-8):415-421. PubMed ID: 30526220
    [Abstract] [Full Text] [Related]

  • 8. Successful alectinib desensitization in a patient with anaplastic lymphoma kinase-positive adenocarcinoma of the lung and alectinib-induced drug rash.
    Anderson BE, Luczak TS, Ries LM, Hoefs GE, Silva-Benedict AC.
    J Oncol Pharm Pract; 2020 Dec; 26(8):2028-2030. PubMed ID: 32476587
    [Abstract] [Full Text] [Related]

  • 9. Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease.
    Nitawaki T, Sakata Y, Kawamura K, Ichikado K.
    BMC Pulm Med; 2017 Dec 06; 17(1):173. PubMed ID: 29207989
    [Abstract] [Full Text] [Related]

  • 10. Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
    Wang Z, Wu R, Li C, Cheng K, Di Y, Lv T, Liu H, Song Y.
    Anticancer Drugs; 2023 Nov 01; 34(10):1069-1075. PubMed ID: 36688904
    [Abstract] [Full Text] [Related]

  • 11. VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
    Hu S, Li Q, Peng W, Feng C, Zhang S, Li C.
    J Thorac Oncol; 2018 May 01; 13(5):e72-e74. PubMed ID: 29703539
    [No Abstract] [Full Text] [Related]

  • 12. ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report.
    Gonzalez-Mosquera LF, Rous FA, Rogers A, Smith N, Goyert G, Gadgeel S.
    Clin Lung Cancer; 2024 Mar 01; 25(2):e77-e80. PubMed ID: 38057186
    [Abstract] [Full Text] [Related]

  • 13. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
    Ning S, Shi C, Zhang H, Li J.
    Medicine (Baltimore); 2021 Dec 23; 100(51):e27999. PubMed ID: 34941039
    [Abstract] [Full Text] [Related]

  • 14. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    Kuo CS, Tung PH, Huang AC, Wang CC, Chang JW, Liu CY, Chung FT, Fang YF, Guo YK, Yang CT.
    BMC Cancer; 2021 Mar 24; 21(1):309. PubMed ID: 33761908
    [Abstract] [Full Text] [Related]

  • 15. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
    Shirasawa M, Kubotaa M, Harada S, Niwa H, Kusuhara S, Kasajima M, Hiyoshi Y, Ishihara M, Igawa S, Masuda N.
    Lung Cancer; 2016 Sep 24; 99():66-8. PubMed ID: 27565916
    [Abstract] [Full Text] [Related]

  • 16. YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation.
    Tsuji T, Ozasa H, Aoki W, Aburaya S, Yamamoto Funazo T, Furugaki K, Yoshimura Y, Yamazoe M, Ajimizu H, Yasuda Y, Nomizo T, Yoshida H, Sakamori Y, Wake H, Ueda M, Kim YH, Hirai T.
    Nat Commun; 2020 Jan 03; 11(1):74. PubMed ID: 31900393
    [Abstract] [Full Text] [Related]

  • 17. Alectinib for advanced ALK-positive non-small-cell lung cancer.
    Ly AC, Olin JL, Smith MB.
    Am J Health Syst Pharm; 2018 Apr 15; 75(8):515-522. PubMed ID: 29467147
    [Abstract] [Full Text] [Related]

  • 18. Revisiting a lower starting dose of alectinib in ALK-Positive non-small cell lung cancer.
    Sacdalan DB, Lucero JA.
    Cancer Treat Res Commun; 2021 Apr 15; 27():100319. PubMed ID: 33515938
    [Abstract] [Full Text] [Related]

  • 19. PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy.
    Nagasaka M, Fisher A, Chowdhury T, Ge Y, Sukari A.
    Clin Lung Cancer; 2021 Jan 15; 22(1):e51-e53. PubMed ID: 32893122
    [No Abstract] [Full Text] [Related]

  • 20. Lung adenocarcinoma with an uncommon CCDC85A-ALK fusion responding to alectinib: A case report.
    Lin J, Wang W, Lin J, Chen R, Cao Y.
    J Cell Mol Med; 2022 Oct 15; 26(20):5326-5329. PubMed ID: 36102237
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.